OBJECTIVES: : Assess the impact of the treatment of urinary disorders of the lower urinary tract related to benign prostatic hypertrophy (BPH) using medical treatment under actual conditions of use. METHODS: A pragmatic cohort of patients treated medically, was followed up for 6 months, using several validated questionnaires: IPSS, MSF4, and SF12. RESULTS: : A total of 146 patients treated with Serenoa Repens (hexanic extract) were evaluated, the mean age was 65.64± 8.82 years, and on average the diagnosis had been made 11 months previously. At 6 weeks, the IPSS was significantly improved (p<0.0001). This improvement in the IPSS score between 6 weeks (11.08±6.17) and inclusion (15.05±6.80) was 4 points. An improvement was also observed at 3 months. At 6 months, the p-value was also significant (p<0.0001). The improvement in the IPSS score between 6 months (7.78±423) and inclusion (14.79±6.90) was 7 points.The physical dimension (50.18±7.39 at inclusion) of the SF12 improved significantly (p=0.0005) from the 6th week (52.46±6.10), an improvement (2.51 points) that was confirmed at 6 months (52.07±6.54) (p=0.0052) in comparison with inclusion (49.56±7.53). The mental dimension (49.18±7.63 at inclusion) of the SF12 improved significantly (p=0.0069) at 6 month (51.81±6.59). Improvement of 2.63 points. The MSF4 was unchanged. CONCLUSIONS: We observed an improvement in the IPSS score from the 6th week; this statistical improvement was confirmed by a significant clinical improvement in the 6th month. This favourable progression is consistent with the improvement observed for both dimensions of the SF12.